NEW YORK (GenomeWeb News) – Complete Genomics today announced an agreement with investment bank MLV & Co. for the potential sale of an aggregate of $30 million of its common stock.
The sale of Complete Genomics' stock would be made on the Nasdaq Global Market under the Mountain View, Calif.-based firm's currently effective Form S-3 at market prices. Shares also may be sold through MLV at negotiated prices or at prices related to the prevailing market price, Complete Genomics said.